| dc.date.accessioned | 2018-06-25T15:09:20Z | |
| dc.date.issued | 2004 | |
| dc.identifier | http://publications.icr.ac.uk/1738/ | |
| dc.identifier.citation | LEUKEMIA & LYMPHOMA, 2004, 45 (1), pp. 179 - 181 | |
| dc.identifier.issn | 1042-8194 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1914 | |
| dc.description.abstract | Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non- Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness. | |
| dc.format.extent | 179 - 181 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.subject | acute myeloid leukaemia (AML) meningeal myelodysplasia non- Hodgkin's lymphoma (NHL) thalidomide acute myelogenous leukemia lymphoid malignancies brain transplantation myelodysplasia therapies | |
| dc.title | Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | |
| dc.type | Journal Article | |
| rioxxterms.licenseref.startdate | 2004 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | |
| pubs.issue | 1 | |
| pubs.notes | none Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non- Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness. | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR | |
| pubs.volume | 45 | en_US |
| pubs.embargo.terms | Not known | |
| dc.contributor.icrauthor | Baird, Richard | |
| dc.contributor.icrauthor | Duddy, James | |
